15 patents
Utility
Galectin-3 inhibiting c-glycosides
16 Jan 24
Compounds, compositions, and methods for treatment and/or prevention of at least one disease, disorder, and/or condition by inhibiting binding of galectin-3 to ligands are disclosed.
John L. Magnani, John M. Peterson, Arun K. Sarkar, Yusufbhai U. Vohra, Indranath Ghosh, Jason Nogueira
Filed: 26 Dec 19
Utility
Heterobifunctional inhibitors of E-selectin and galectin-3
19 Dec 23
Compounds, compositions, and methods for treatment and/or prevention of at least one disease, disorder, and/or condition by inhibiting binding of an E-selectin, galectin-3, or E-selectin and galectin-3 to ligands are disclosed.
John L. Magnani, John M. Peterson, Arun K. Sarkar, Yusufbhai U. Vohra, Indranath Ghosh, Jason Nogueira
Filed: 26 Dec 19
Utility
Highly potent multimeric e-selectin antagonists
10 Oct 23
Compounds, compositions, and methods for treatment and/or prevention of at least one disease, disorder, and/or condition by inhibiting binding of an E-selectin to an E-selectin ligand are disclosed.
John L. Magnani, John M. Peterson, Myung-Gi Baek
Filed: 15 Jun 21
Utility
Methods of mobilizing marrow infiltrating lymphocytes and uses thereof
1 Aug 23
Methods are disclosed for the mobilization of marrow infiltrating cells (MILs) using E-selectin antagonists for the treatment of disorders such as cancer.
John L. Magnani, William Fogler
Filed: 29 Nov 18
Utility
Methods for treating acute myeloid leukemia and related conditions
25 Jul 23
Methods for treating or inhibiting cancer and/or one or more related conditions by administering to a subject in need thereof an effective amount of a compound of Formula (I), a prodrug thereof, or a pharmaceutically acceptable salt of any of the foregoing.
Helen M. Thackray, Henry H. Flanner, Curt D. Wolfgang
Filed: 4 Mar 19
Utility
Heterobifunctional inhibitors of E-selectin and galectin-3
10 Jan 23
John L. Magnani, John M. Peterson, Arun K. Sarkar, Yusufbhai U. Vohra, Hong-Woon Yang
Filed: 28 Dec 18
Utility
Combination of T-cell checkpoint inhibitors with inhibitors of e-selectin or CXCR4, or with heterobifunctional inhibitors of both E-selectin and CXCR4
6 Sep 22
Compositions and methods for the treatment of diseases, disorders, and/or conditions associated with the increased regulatory T lymphocyte cell function, comprising the administration of T-cell checkpoint inhibitors in combination with E-selectin inhibitors, C—X—C Motif Chemokine Receptor 4 (CXCR4) receptor inhibitors, and/or heterobifunctional inhibitors that comprise at least one E-selectin inhibitor linked to at least one CXCR4 receptor inhibitor, are disclosed.
John L. Magnani, William E. Fogler
Filed: 7 Aug 17
Utility
E-selectin antagonist compounds, compositions, and methods of use
17 May 22
Methods and compositions using E-selectin antagonists are provided for the treatment and prevention of diseases and disorders treatable by inhibiting binding of E-selectin to an E-selectin ligand.
John L. Magnani, Arun K. Sarkar, Myung-Gi Baek, Frank E. Anderson, III, Yanhong Li
Filed: 17 Aug 20
Utility
Methods for the treatment and/or prevention of cardiovascular disease by inhibition of E-selectin
5 Apr 22
New methods for treating and/or preventing cardiovascular disease including, for example, myocardial infarction and atherosclerosis, by the use of at least one E-selectin inhibitor and compositions comprising the same are disclosed.
John L Magnani, Matthias P Nahrendorf
Filed: 1 Mar 17
Utility
Galactopyranosyl-cyclohexyl derivauves as E-selectin antagonists
14 Dec 21
Compounds, compositions, and methods for treatment and/or prevention of at least one disease, disorder, and/or condition by inhibiting binding of an E-selectin to an E-selectin ligand are disclosed.
John L Magnani, John M Peterson, Arun K Sarkar, Yusuf U Vohra, Myung-Gi Baek
Filed: 12 Mar 18
Utility
Highly potent multimeric e-selectin antagonists
27 Jul 21
Compounds, compositions, and methods for treatment and/or prevention of at least one disease, disorder, and/or condition by inhibiting binding of an E-selectin to an E-selectin ligand are disclosed.
John L. Magnani, John M. Peterson, Myung-Gi Baek
Filed: 6 Oct 17
Utility
Glycomimetic inhibitors of PA-IL and PA-IIL lectins
29 Jun 21
Compounds, compositions, and methods for the diagnosis and/or treatment of medical conditions involving infections with and colonization by Pseudomonas bacteria including, for example, Pseudomonas aeruginosa in the lungs of patients with cystic fibrosis are described.
John L Magnani, Arun K. Sarkar
Filed: 18 Jan 17
Utility
E-selectin antagonist compounds, compositions, and methods of use
7 Sep 20
Methods and compositions using E-selectin antagonists are provided for the treatment and prevention of diseases and disorders treatable by inhibiting binding of E-selectin to an E-selectin ligand.
John L. Magnani, Arun K. Sarkar, Myung-Gi Baek, Frank E. Anderson, III, Yanhong Li
Filed: 19 Nov 19
Utility
E-selectin antagonist compounds, compositions, and methods of use
6 Jan 20
Methods and compositions using E-selectin antagonists are provided for the treatment and prevention of diseases and disorders treatable by inhibiting binding of E-selectin to an E-selectin ligand.
John L. Magnani, Arun K. Sarkar, Myung-Gi Baek, Frank E. Anderson, III, Yanhong Li
Filed: 18 Sep 17
Utility
Heterobifunctional inhibitors of E-selectins and CXCR4 chemokine receptors
30 Dec 19
Compounds, compositions, and methods for treatment and/or prevention of cancer and inflammatory diseases, and for releasing cells such as stem cells (e.g., bone marrow progenitor cells) into circulating blood and enhancing retention of the cells in the blood are disclosed.
John L. Magnani, Arun K. Sarkar, John M. Peterson
Filed: 30 Nov 15
- Prev
- 1
- Next
Patents are sorted by USPTO publication date, most recent first